These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38945365)

  • 1. Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I Protein.
    Ayoun Alsoud R; Le Moan N; Holten-Andersen L; Knudsen T; Lennernäs H; Simonsson USH
    J Pharm Sci; 2024 Sep; 113(9):2895-2903. PubMed ID: 38945365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203).
    Kim J; Kim TH; Choi J; Nam K; Shin BS; Shin S
    Biomed Pharmacother; 2023 Nov; 167():115441. PubMed ID: 37696082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
    Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
    Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
    Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
    Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling.
    Kang HE; Lee MG
    Arch Pharm Res; 2011 Nov; 34(11):1779-88. PubMed ID: 22139680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
    Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
    Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
    Pierrillas PB; Henin E; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
    Invest New Drugs; 2020 Dec; 38(6):1796-1806. PubMed ID: 32451663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interspecies modeling and prediction of human exenatide pharmacokinetics.
    Chen T; Mager DE; Kagan L
    Pharm Res; 2013 Mar; 30(3):751-60. PubMed ID: 23229855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
    Zou P; Zheng N; Yu Y; Yu S; Sun W; McEachem D; Yang Y; Yu LX; Wang S; Sun D
    J Pharm Pharm Sci; 2012; 15(2):265-80. PubMed ID: 22579006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
    Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
    MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2.
    Lee WS; Shim SR; Lee SY; Yoo JS; Cho SK
    Drug Des Devel Ther; 2018; 12():495-504. PubMed ID: 29563774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.
    Robbie G; Chiou WL
    Pharm Res; 1998 Oct; 15(10):1630-6. PubMed ID: 9794508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allometric scaling for predicting human clearance of bisphenol A.
    Collet SH; Picard-Hagen N; Lacroix MZ; Puel S; Viguié C; Bousquet-Melou A; Toutain PL; Gayrard V
    Toxicol Appl Pharmacol; 2015 May; 284(3):323-9. PubMed ID: 25759244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interspecies scaling and comparisons in drug development and toxicokinetics.
    Ings RM
    Xenobiotica; 1990 Nov; 20(11):1201-31. PubMed ID: 2275215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
    Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
    MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran.
    Ayyar VS; Song D
    J Pharm Sci; 2024 Jan; 113(1):176-190. PubMed ID: 37871778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.